# Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

> **NCT06129851** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 90 (estimated)

## Conditions studied

- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **RADIATION:** Brachytherapy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Dual X-ray Absorptiometry
- **RADIATION:** External Beam Radiation Therapy
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** PSMA PET Scan
- **OTHER:** Questionnaire Administration
- **DRUG:** Relugolix

## Key facts

- **NCT ID:** NCT06129851
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2025-10-23
- **Final completion:** 2026-10-23
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129851, "Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06129851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*